
Open R&D Models Increase Chances for Late-Stage Success
The Virtual Press Office website reported that Deloitte has released a report showing that drugs sourced via open innovation are three times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach. The study also asserts that open innovation may emerge as a quicker and less expensive avenue
Comments Off on Open R&D Models Increase Chances for Late-Stage Success • Read this story »